NADAC acquisition cost data for RYTARY ER 36.25 MG-145 MG CAP. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 64896066201 | $3.70 | 2022-02-01 | Rx |
| 64896066201 | $3.70 | 2022-02-01 | Rx |
| 64896066201 | $3.70 | 2022-02-01 | Rx |
| 64896066201 | $3.70 | 2022-02-01 | Rx |
| 64896066201 | $3.70 | 2022-02-01 | Rx |
| 64896066201 | $3.70 | 2022-02-01 | Rx |
| 64896066201 | $3.70 | 2022-02-01 | Rx |
| 64896066201 | $3.70 | 2022-02-01 | Rx |
| 64896066201 | $3.70 | 2022-02-01 | Rx |
| 64896066201 | $3.70 | 2022-02-01 | Rx |
Generic: Carbidopa/Levodopa | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $134.3M | 149,019 | 21,453 | $3.38 |
| 2020 | $164.5M | 168,381 | 23,956 | $3.51 |
| 2021 | $192.4M | 179,777 | 26,929 | $3.73 |
| 2022 | $228.3M | 192,204 | 29,141 | $4.13 |
| 2023 | $266.9M | 209,452 | 32,157 | $4.49 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $41.5M | 30,496 | 5,174 |
| Texas | $29.3M | 24,027 | 4,231 |
| Florida | $21.0M | 17,181 | 2,998 |
| New York | $16.2M | 13,487 | 2,076 |
| Ohio | $9.2M | 6,599 | 1,004 |
| Pennsylvania | $8.1M | 6,724 | 1,071 |
| Illinois | $7.4M | 5,857 | 898 |
| Virginia | $7.3M | 5,492 | 952 |
| Washington | $7.2M | 4,462 | 730 |
| Massachusetts | $6.8M | 4,911 | 729 |
| Colorado | $6.6M | 4,492 | 720 |
| Arizona | $6.6M | 4,822 | 931 |
| New Jersey | $6.0M | 4,771 | 795 |
| Michigan | $6.0M | 4,293 | 710 |
| Maryland | $5.5M | 3,591 | 609 |
| Minnesota | $5.4M | 3,312 | 538 |
| North Carolina | $5.3M | 3,836 | 686 |
| Wisconsin | $5.2M | 4,293 | 609 |
| Connecticut | $5.2M | 4,419 | 647 |
| Georgia | $4.6M | 3,877 | 665 |
| Puerto Rico | $4.3M | 6,982 | 734 |
| Louisiana | $4.3M | 4,272 | 611 |
| South Carolina | $4.1M | 2,435 | 468 |
| Tennessee | $4.1M | 3,314 | 606 |
| Oregon | $3.6M | 2,248 | 361 |
| Oklahoma | $3.4M | 2,482 | 404 |
| Indiana | $2.9M | 2,612 | 416 |
| Kansas | $2.6M | 2,253 | 299 |
| Missouri | $2.5M | 2,010 | 380 |
| Kentucky | $2.4M | 1,960 | 304 |
| District of Columbia | $2.3M | 1,518 | 371 |
| Nevada | $2.1M | 1,326 | 269 |
| Arkansas | $2.0M | 1,758 | 278 |
| Nebraska | $1.8M | 1,665 | 204 |
| New Hampshire | $1.8M | 1,106 | 249 |
| North Dakota | $1.1M | 887 | 104 |
| Utah | $1.1M | 704 | 136 |
| Alabama | $1.1M | 965 | 175 |
| Idaho | $1.0M | 812 | 142 |
| Delaware | $965.0K | 683 | 125 |
| Hawaii | $950.4K | 544 | 99 |
| Mississippi | $909.9K | 945 | 155 |
| Iowa | $888.6K | 930 | 121 |
| West Virginia | $876.6K | 868 | 156 |
| Maine | $759.3K | 642 | 96 |
| New Mexico | $692.3K | 537 | 114 |
| Rhode Island | $677.1K | 652 | 87 |
| Vermont | $465.3K | 342 | 62 |
| Montana | $400.3K | 496 | 67 |
| South Dakota | $327.1K | 316 | 42 |
| Alaska | $98.9K | 113 | 21 |
| Wyoming | $70.1K | 67 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.